Houston, Texas 77030

  • Myelodysplastic Syndrome


The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.


Inclusion Criteria: - Poor prognosis AML or MDS - Histological confirmation of diagnosis - White blood cell count less than or equal to 30,000/mm3 - Adequate hepatic and renal function documented within 14 days prior to registration - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - No evidence of preexisting uncontrolled hypertension - Not a suitable candidate for chemotherapy - No prior systemic chemotherapy treatment for AML or MDS or treatment with an anti-angiogenesis agent Exclusion Criteria: - Patients must not have exclusion criteria. - Candidate for chemotherapy - Patients with AML M3 (acute promyelocytic leukemia) - Conditions that might confound the evaluation of safety or efficacy or increase patient risk.



Primary Contact:

Study Director
Pfizer CT.gov Call Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.